Craig-Hallum bullish on Opus Genetics, initiates with a Buy

As previously reported, Craig-Hallum analyst Albert Lowe initiated coverage of Opus Genetics (IRD) with a Buy rating and $6 price target The firm sees significant upside potential around the company’s pipeline of AAV gene therapies for inherited retinal diseases. Opus’s lead asset OPGx-LCA5 provides POC of the company’s approach with dramatic vision improvements in all four legally blind LCA5 patients treated in the ongoing Phase I/II trial. Opus’s robust pipeline, led by OPGx-LCA5 and OPGxBEST1, represents meaningful commercial opportunities with the potential to improve vision in rare blindness diseases with a one-time treatment, Craig-Hallum argues. The firm notes that upcoming catalysts include initial data from the cohort of pediatric LCA5 patients expected in 3Q25 and initial BEST1 data in late-2025/early-2026.